PT Prodia Widyahusada Tbk · IDX:PRDA
PT Prodia Widyahusada Tbk — FY2023 Earnings Presentation
27 slides from PT Prodia Widyahusada Tbk's earnings presentation, 2024
Slide 1: FY2023 Results Update
FY2023 Results Update PT Prodia Widyahusada Tbk | P R D A . J K Prodia.co.id
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Corporate Overview
CORPORATE OVERVIEW Prodia.co.id
Slide 4: 2023 Performance Highlight
2023 Performance Highlight 50+ More than 50 years experience in Clinical Lab Industry since 1973 IDR 2,222 Billion FY2023 Revenue (+1.9% yoy), CAGR 5yrs (+6.8%) Has the most recognized Brand in Indonesia >2.8 Million Largest private independent clinical lab FY2023 Visit (+0.4% yoy), CAGR 5yrs (+2.7%
Slide 5: Extensive Milestone to Grow
Extensive Milestone to Grow 2017 • Received Westgard Six Sigma 2011 Certification & KALK Next-Gen Lab: Accreditation • 18 new test launched in preventive & predictive 2008 • Established Prodia • Develop Prodia Mobile screening, diagnostic, and targeted therapy • Establishment of ChildLab Prodia Nati
Slide 6: Experienced Management Team
Experienced Management Team With more than 20 years experience in delivering growth and innovation of Prodia Years of 51 Years of 51 Experience 40 Years of 49 Years of 32 Years of Experience Experience Experience Experience Gunawan Endang Joseph Fellipus Keri Lestari Andi Wijaya Prawiro Soeharto Pet
Slide 7: Shareholders Composition
Shareholders Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 15% 28% Distributor for Contract Research, therapy Distributor for medical Research and banking of healthcare equipment Organization stem cell products PT Prodia Widyahusada Tbk Nationwide Outlet Network across Indonesia Occup
Slide 8: Investment Highlight
INVESTMENT HIGHLIGHT Prodia.co.id
Slide 9: Largest Independent Labs Chain
Largest Independent Labs Chain Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2020-2022) (Billion IDR) 3YRS CAGR 3YRS CAGR 39.5% 37.9% 40.5% 5.8% 27.8% 33.1% 28.0% 7.1% 7,225 2020 2021 2022 2,737 5,455 2,209 4,874 1,926 32.7% 29.0% 31.5% Prodia Next 5 Players Com
Slide 10: Strong Operational Track Record
Strong Operational Track Record Visits Revenue (in million) (in IDR Trillion) 2.8 2.22 CAGR CAGR 6.8% 2.7% 2.4 1.60 Prodia has generated continuous revenue growth 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 and increasing number of visits Revenue per Visit EBITDA (in IDR ‘000) that s
Slide 11: Comprehensive Service Offering
Comprehensive Service Offering With multiple customer segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, General Medical offering the most Genomic Testing Preventive Treatment Check-Up Services comprehensive ran
Slide 12: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved “Hub and spoke” model offers Centralized information scalable platform reducing Prodia Clinical Labs, Hospitals with integrated IT and Other Clinics may refer Prodia Re
Slide 13: Maintain Strong and Long-Term Relationship with Medical Community
Maintain Strong and Long-Term Relationship with Medical Community Strong relationships through the work Introduced new tests, such as NIPT ProSafe, Amino of more than 400 Marketing and Acid Profile, Fatty Acid Profile, CArisk, DIArisk, Liquid Laboratory Information Service biopsy EGFR Mutation, New
Slide 14: Pioneer in New Lab Testing; Digital Healthcare Platform
Pioneer in New Lab Testing Offer more than 3,000 type of testing, with referral Target to launch minimum 10 new Partnership to NUH Singapore and Quest Diagnostic US testing every year One of The Largest Digital Healthcare Platform One Stop Health Solution Apps Walk-in Apps Doctor Referral Apps U by
Slide 15: Market Overview & Growth Strategy
MARKET OVERVIEW & GROWTH STRATEGY Prodia.co.id
Slide 16: 2023 Indonesia Economic Outlook
2023 Indonesia Economic Outlook Stay Resilient with Positive Growth Forecast 5.05% Indonesia’s GDP Growth for 2023 Global economic uncertainty expected to GDP Growth continue in 2024 and 2023 2024 lead an impact on consumption and World 2.7% 3.0% investments. However, Government remains Indonesia 5.
Slide 17: Company's Growth Strategy
Company's Growth Strategy Expand our presence and grow our Orchestrate highest quality health ecosystem network of outlets in both physical and and leading digital health ecosystem in digital channel in Indonesia Indonesia Upgrade existing clinical laboratories to Reinforce Company's subsidiary: Pro
Slide 18: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Molecular Mass Spectrometry & Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Anatomical Laboratory Cancer Molecular Pathology Diagnostic Laboratory Advance Immunology Advance & Flowcytome
Slide 19: Business Update
BUSINESS UPDATE Prodia.co.id
Slide 20: Outlet Development
Outlet Development 2016-2023 Outlet Development 2024 Outlet Development Target 259 283 292 287 267 259 276 295 2 5 7 4** 4** 4** 4** 4** 9 11 14 14 12 9 11 10 1-2 30+ 98 Clinical Labs POC Outlets 118 122 108 113 133 130 128 5+ 148 Hospital Labs 129 147 148 148 148 136 143 Management* *includes hospi
Slide 21: Customer Centric Model
Customer Centric Model To deliver solution for customer needs • Routine, Esoteric, Genomic Tests Professional Contact Centre • Wellness Package • Call Centre 1500-830 • Disease Screening • Prodia Mobile • Chat WhatsApp 0855-1500-830 • Prodia Mobile for Doctor Package • Chat bot TANIA (Tanya Prodia)
Slide 22: Financial Update
FINANCIAL UPDATE Prodia.co.id
Slide 23: FY2023 Revenue
FY2023 Revenue Revenue (Audited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion FY18-FY23 CAGR +6.8% 2018 2019 2020 2021 2022 2023 ▪ Revenue growth in FY22-FY23 FY23 mostly Growth: +1.9% supported by volume test and tests per visit 2,652 4Q23: increase. 3Q23: 610.4 549.1 2,182 2,222 2Q2
Slide 24: FY2023 Gross Profit & Net Income
FY2023 Gross Profit & Net Income Gross Profit Net Income in IDR Billion In IDR Billion FY18-FY23 CAGR +6.9% FY18-FY23 CAGR +8.1% FY22-FY23 FY22-FY23 Growth: -0.6% 623.2 Growth: -30.2% 1,633 59.7% 1,327 1,319 58.9% 23.5% 61.6% 14.3% 1,041 1,046 60.8% 371.6 943 11.0% 12.1% 59.4% 17.0% 268.7 259.3 210.
Slide 25: FY2023 COGS & OPEX
FY2023 COGS & OPEX COGS OPEX in IDR Billion In IDR Billion FY18-FY23 CAGR +6.6% FY18-FY23 CAGR +5.8% COGS to revenue Opex to revenue FY22-FY23 FY22-FY23 Direct Cost Growth: +5.7% G&A Expense Growth: +14.6% Indirect Cost Marketing Expense 146 74 48.1% 200 42 46 125 157 50 46 30 45.9% 114 126 47.5% 40
Slide 26: FY2023 Financial Summary
FY2023 Financial Summary (in IDR Bn) FY2023 FY2022 Change (in IDR Bn) FY2023 FY2022 Change Revenue 2,222.5 2,181.6 +1.9% Total Asset 2,708.1 2,669.6 +1.4% Gross Profit 1,319.2 1,327.1 -0.6% Total Equity 2,360.6 2,311.1 +2.1% EBIT 308.5 447.0 -31.0% EBT 338.9 470.3 -27.9% Net Income 259.3 371.6 -30.2
Slide 27: Thank You
THANK YOU For further Information: PT Prodia Widyahusada Tbk Prodia Tower. Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: [email protected] @prodia_lab @prodia_lab @prodia_lab 1500 830 Prodia.co.id